Skip to main content
 

Advocate Spotlight: Affiliates on the Hill

Friday, June 29, 2018

Each month, the Cancer Policy Insitute will be profiling advocates who have been engaged in advocacy in their home state, their community, with elected officials, and more. Read on to learn more about our affiliate leaders visits on Capitol Hill this month and their individual experiences with advocacy. If you are interested in learning more about policy, advocacy, and ways to get involved, sign up to be a part of the Grassroots Network!

Advocate Spotlight: Libby Mullin, Washington, D.C.

Monday, May 14, 2018

Each month, the Cancer Policy Insitute will be profiling advocates who have been engaged in advocacy in their home state, their community, with elected officials, and more. Read on to learn more about our featured advocate for the month of May and her years in advocacy on Capitol Hill and with her own consulting practice. If you are interested in learning more about policy, advocacy, and ways to get involved, sign up to be a part of the Grassroots Network!

Advocate Spotlight: Lee Tomlinson, Los Angeles, California

Thursday, April 12, 2018

Each month, the Cancer Policy Insitute will be profiling advocates who have been engaged in advocacy in their home state, their community, with elected officials, and more. Read on to learn more about our featured advocate for the month of April and his passion for promoting patient-centered, heart-driven compassionate care. If you are interested in learning more about policy, advocacy, and ways to get involved, sign up to be a part of the Grassroots Network!

Dr. Jill Biden Continues Conversations with Caregivers

Monday, March 26, 2018

Dr. Jill Biden continued the Biden Cancer Initiative’s effort to share common challenges and lessons of the cancer experience when she met with caregiver George Hutt in Natick, Massachusetts.

Advocate Spotlight: Miranda Johnson, Washington, D.C.

Tuesday, March 13, 2018

"Having a personal connection to an issue is part of what will make the work that you do resonate with so many people. It will drive your passion to do more research, learn about the issue, and look for ways in which you can contribute and help people."

Read more from Miranda about discovering the importance of being an advocate and sharing your story.

Dr. Jill Biden Hears from CSC Caregiver at SXSW

Monday, March 12, 2018

Over the weekend, you might have seen the hashtag #cancerFIERCE coming out of the social media coverage of South by Southwest (SXSW).

That is because Dr. Jill Biden and other leaders with the Biden Cancer Initiative were at the gathering in Austin, TX to put the organization’s work front and center at a gathering of leading thinkers and entrepreneurs.

As part of Dr. Biden’s #cancerFIERCE visit to SXSW, she met with cancer patients, caregivers, and advocates, including Mike DiMascio.

Advocate Spotlight: Bev Soult, President/CEO of CSC Central Ohio

Thursday, February 1, 2018

"By becoming an advocate, at any level, we are able to unify our organization throughout the nation and become one voice for Cancer Support Community/Gilda’s Club, advocating for all cancer patients and survivors."

Read more from Bev about her own experience in advocacy, and her advice for those wanting to get more involved.

Last Ditch Repeal Efforts Will Harm Cancer Patients

Wednesday, September 20, 2017

Just when we started to hope that the debate over the repeal and replacement of the Affordable Care Act (ACA) was at an end, a new plan to repeal and replace the law has been introduced. Senators Lindsey Graham (R-SC) and Bill Cassidy (R-LA) have introduced a bill that would be devastating to individuals living with chronic illness including those who have been impacted by cancer.

FDA Reauthorization Bill a Win for Psychosocial Care

Tuesday, August 29, 2017

On August 17, 2017, the Food and Drug Administration Reauthorization Act of 2017 (FDARA) became law. FDARA is primarily responsible for funding the Food and Drug Administration (FDA) so that the agency can review and approve drugs and devices in a timely manner. It also contains provisions that provide guidance for manufacturers on how they conduct research on the drugs and devices they are developing.

Authors